Sanofi
Open enrollment across a mixed-phase pipeline
According to ClinicalTrials.gov-derived indexes, Sanofi sits in the top decile of US sponsors by registered trial count (#47 of 15,742 sponsors by registered trial count).
Sanofi: 713 sponsored US clinical trials, 69 recruiting.
Sanofi sponsors 713 registered US clinical trials on ClinicalTrials.gov, 69 of them currently recruiting, and 490 completed. 364 of these trials are in Phase 3-4 (later-stage) and 316 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Dermatitis, Atopic, with 9 trials.
Top-decile sponsor footprint
Sanofi ranks in the top decile of sponsors by registered trial count (#47 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
490 of 597 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (82.1%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
713 total, page 14 of 15
Evaluating the Use of SR34006 Compared to Warfarin or Acenocoumarol in Patients With Atrial Fibrillation (AMADEUS)
NCT00070655
Evaluation of the Hypnotic Properties of Zolpidem-MR 12.5 mg and Zolpidem 10 mg Marketed Product Compared to Placebo in Patients With Primary Insomnia
NCT00630175
PREVAIL: PREvention of VTE After Acute Ischemic Stroke With LMWH Enoxaparin ( - VTE: Venous Thromboembolism - LMWH: Low Molecular Weight Heparin)
NCT00077805
The ORIGIN Trial (Outcome Reduction With Initial Glargine Intervention)
NCT00069784
Fasturtec TLS Treatment / Prophylysis
NCT00651911
The Efficacy and Safety of Irbesartan 150/12.5 mg and 300/25 mg in Patients With Mild Hypertension
NCT00562809
Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE W)
NCT00243178
Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE A)
NCT00249873
Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE I)
NCT00249795
SR34006 Compared to Vitamin K Antagonist (VKA) in the Treatment of Pulmonary Embolism
NCT00062803
Safety and Efficacy Trial Evaluating the Use of SR34006 in the Treatment of Deep Vein Thrombosis (DVT)
NCT00067093
Fexofenadine (Allegra®) in Healthy Adults Who Have Been Identified as Slow Metabolizers for Desloratadine
NCT00636870
Single-Center, Double-Blind, Randomized , Parallel Study Comparing Onset of Action, Efficacy & Safety of a Single-Dose of Fexofenadine HCl 180 mg vs Montelukast Na 10 mg & Placebo in Treating Seasonal Allergic Rhinitis Subjects in an Allergen Exposure Unit
NCT00637611
Fexofenadine HCl 180 mg, Montelukast Sodium 10 mg and Placebo in Suppression of Wheal and Flare Induced by Seasonal Allergen
NCT00638118
The Efficacy, Onset of Effect, and Safety of Alfuzosin Once Daily in the Treatment of Lower Urinary Tract Symptoms of Benign Prostatic Hyperplasia: A Randomized, Placebo-Controlled Trial Using an Acute International Prostate Score
NCT00540891
Clopidogrel as Adjunctive Reperfusion Therapy - Thrombolysis in Myocardial Infarction
NCT00714961
Fexofenadine HCl 180 mg, Desloratadine 5 mg and Placebo in Suppression of Wheal and Flare Induced by Histamine
NCT00637585
AMS VS MOXI Ketek vs Avelox in AMS
NCT00537563
Compare Blood Sugar Level Between Lantus in the Morning and Other Insulins in Type 1 Diabetes Adolescents
NCT00046501
Comparative Study Evaluating the Effects of Fexofenadine HCI 180 mg With Orange Juice Versus Placebo With Orange Juice in a Skin Wheal and Flare Challenge Model.
NCT00547768
Efficacy and Safety of Rimonabant as an Aid to Maintenance of Smoking Cessation
NCT00459173
TREE-2: Three Regimens of Eloxatin in Advanced Colorectal Cancer
NCT00399750
Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment Thrombolysis in Myocardial Infarction - Study 25 (ExTRACT-TIMI25)
NCT00077792
Concomitant Radiation and Cisplatin With and Without Tirapazamine in Treatment of Advanced Head and Neck Cancer
NCT00094081
Glimepiride vs Metformin as Monotherapy in Pediatric Subjects With Type 2 Diabetes Mellitus
NCT00353691
Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management and Avoidance (CHARISMA)
NCT00050817
Risedronate in the Prevention of Osteoporosis in Postmenopausal Women
NCT00402441
Comparison of the Efficacy and Safety of 2 Oral Doses of Rimonabant, 5 mg/Day or 20 mg/Day, Versus Placebo, as an Aid to Smoking Cessation (STRATUS US)
NCT00358228
Impact of Vertebral Fracture Knowledge on Persistence in Subjects Taking Glucocorticoid Therapy
NCT00616694
Efficacy and Safety Study of NV1FGF in Patients With Severe Peripheral Artery Occlusive Disease.
NCT00798005
Efficacy and Safety of Fexofenadine in Mild to Moderate Persistent Asthma
NCT00044811
Efficacy and Safety of Fexofenadine in Mild to Moderate Persistent Asthma
NCT00044824
EXCLAIM:Extended Prophylaxis for Venous ThromboEmbolism (VTE) in Acutely Ill Medical Patients With Prolonged Immobilization
NCT00077753
Long-Term Safety Performance of Fexofenadine in Asthma
NCT00045955
Lantus in Prediabetes
NCT00348972
Gene Expression and Tolerability Study of NV1FGF in Patients With Peripheral Artery Occlusive Disease Planned to Undergo Major Amputation
NCT01157143
HUPS: Hyalgan Use in Painful Shoulder
NCT00377624
Insulin Glargine [rDNA Origin] Injection vs Pioglitazone as add-on Therapy in Patients Failing Monotherapy With Sulfonylurea or Metformin
NCT00384215
Docetaxel in Breast Cancer
NCT00312208
American-Australian-African Trial With Dronedarone in Patients With Atrial Fibrillation or Atrial Flutter for the Maintenance of Sinus Rhythm
NCT00259376
A Phase II Trial of Adjuvant Docetaxel in Patients At High Risk of Relapse Following Prostatectomy
NCT00069888
Determine Whether Glycemic Control is Different Between Lantus & a 3rd Oral Agent When Failure With Other Treatment
NCT00046462
Rimonabant in Obesity Over a 2-Year Duration (RIO-Europe)
NCT00386061
Obese Patients With Type 2 Diabetes
NCT00029848
Obese Patients With Untreated Dyslipidemias
NCT00029835
SYNERGY: Open Study of Enoxaparin Versus Unfractionated Heparin in Patients With Acute Coronary Syndromes
NCT00043784
Safety Study of Vasopressin V2 Receptor Antagonist on Patients With Severe Chronic Heart Failure (AQUAVIT).
NCT00032747
Obese Patients With or Without Comorbidities (RIO-North America)
NCT00029861
Lantus Versus Humalog Mix as add-on Therapy in Type Diabetes Patients Failing Sulfonylurea and Metformin Combination Treatment
NCT01336751
Comparison of Insulin Glargine and NPH Human Insulin in Progression of Diabetic Retinopathy in Type 2 Diabetic Patients
NCT00174824
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 147 |
| Phase 2 | 169 |
| Phase 3 | 295 |
| Phase 4 | 69 |
What is open in the Sanofi pipeline
69 recruiting of 713 indexed (10% open); 490 completed (69%).
Phase mix: 364 late (III/IV) vs 316 early (I/II) (balanced across stages).
Top condition: Dermatitis, Atopic (9 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Sanofi: open-pipeline peers nationwide
Peers matched on 713 registered trials and 10% open enrollment, not the therapeutic-area sidebar.
Sanofi sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 713 trials (± recruiting share)
- Icahn School of Medicine at Mount Sinai · 708 trials · 23% recruiting
- University of Miami · 721 trials · 20% recruiting
- Weill Medical College of Cornell University · 701 trials · 18% recruiting
- The University of Texas Health Science Center, Houston · 732 trials · 20% recruiting
Sponsors near 10% open enrollment (± trial volume)
- Children's Hospitals and Clinics of Minnesota · 10% recruiting · 31 trials
- Cytokinetics · 10% recruiting · 31 trials
- Children's Oncology Group · 10% recruiting · 342 trials
- University of North Carolina, Chapel Hill · 10% recruiting · 1,109 trials
Related
What to do with this Sanofi page
713 registered trials is a research-attention snapshot, not an endorsement of Sanofi or any single study.
- 69 of Sanofi's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Dermatitis, Atopic is the condition Sanofi studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Dermatitis, Atopic trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Sanofi pipeline card: 713 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.